GTBP News and Press, GT Biopharma Inc. From 06/10/19

TAMPA, Florida , June 10, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (OTCQB: GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE) platform and Multi-Target Directed Bispecific Drug Conjugate (MTBDC) plat...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol...

TAMPA, Florida , May 30, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE) platform and Multi-Target Directed Bispecific Drug Conjugate (MTBDC) platfor...

TAMPA, Florida , May 29, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (OTC: GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE) platform and Multi-Target Directed Bispecific Drug Conjugate (MTBDC) platfor...

TAMPA, Florida , April 25, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary NK-engager (TriKE) platform and Multi-Target Bispecific Drug Conjugate (MTBDC) platform,...

GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota Canada NewsWire TAMPA, Florida, April 24, 2019 TAMPA, Florida , April 24, 2019 /CNW/ -- GT Biopharma, ...

GT Biopharma ( OTCQB:GTBP ) announces that the authorities at the University of Minnesota have signed off on a Phase 1 clinical trial evaluating NK-engager (TriKE) candidate GTB-3550 in patients with acute myelogenous leukemia, myelodysplastic syndrome and mastocytosis. More news on: GT ...

TAMPA, Florida , April 8, 2019 /PRNewswire/ --GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary NK-engager (TriKE) platform and Multi-Target Bispecific Drug Conjugate (MTBDC) platform, an...

DENVER, Colo., March 26, 2019- (24/7MarketNews via COMTEX) Venture Market News for March 26, 2019. Predictive Technology Group Completes Acquisition of Taueret Laboratories SALT LAKE CITY, March 26, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in th...